View Older Stories View More Recent Stories
-
Medtronic, Inc. (MDT) PT Raised to $105 at Stifel
-
Medtronic begins U.S. study of Hugo robotic surgery system for gynecology
-
Needham: 'we believe that the Section 232 investigation creates a new overhang for the already beleaguered medical device sector'
-
Stifel: Electrophysiology Market Growth is Healthy
-
Piper Sandler on calls with diabetes clinicians
-
Piper Sandler Reiterates Neutral Rating on Medtronic, Inc. (MDT)
-
Orchestra BioMed presents data showing sustained blood pressure drops
-
Medtronic Hugo robot system meets hernia repair study endpoints
-
FDA clears Medtronic's MiniMed 780G system for type 2 diabetes use
-
Orchestra BioMed publishes clinical data on blood pressure therapy
-
TD Cowen Highlights 'Huge Growth Opportunity' for Medtronic, Inc. (MDT)
-
Wolfe Research Reiterates Peerperform Rating on Medtronic, Inc. (MDT)
-
Medtronic, Inc. (MDT) PT Raised to $96 at Truist Securities
-
Medtronic, Inc. (MDT) PT Raised to $95 at UBS
-
TD Cowen on Medtronic, Inc. (MDT): 'Pullback Seems Excessive'
-
Medtronic, Inc. (MDT) PT Raised to $103 at RBC Capital
-
Medtronic, Inc. (MDT) PT Raised to $98 at Bernstein SocGen Group
-
Medtronic, Inc. (MDT) PT Raised to $111 at Leerink Partners
-
Medtronic, Inc. (MDT) PT Raised to $100 at Wells Fargo
-
Mizuho Reiterates Outperform Rating on Medtronic, Inc. (MDT)
-
BTIG Reiterates Neutral Rating on Medtronic, Inc. (MDT)
-
Medtronic, Inc. (mdt) PT Raised to $107 at Evercore ISI
-
Medtronic, Inc. (MDT) PT Raised to $90 at Stifel
-
Increasing unusual put option volume: OPEN VKTX XP PANW JEPI MSTZ ONDS JMIA HOG PTIR HD RGTI USAR COMM MDT
-
TD Cowen Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
Truist Securities Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Morgan Stanley on Medtronic, Inc. (MDT): 'Positive signs, though slightly soft organic'
-
Leerink Partners Positive on Medtronic, Inc. (MDT)
-
Goldman on Medtronic, Inc. (MDT), 'believe investors had expected total organic growth acceleration to follow the strong performance in CAS'
-
Raymond James on Medtronic, Inc. (MDT) Earnings: 'All in, this result and guide fell short of our elevated expectations'
-
Stifel Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Mizuho on Medtronic, Inc. (MDT): 'Largely Inline Print Likely Overshadowed by New Board Appointees'
-
Medtronic appoints two directors, forms board committees after Elliott talks
-
Medtronic (MDT) Tops Q1 EPS by 3c, Beats on Revenue; Offers FY26 EPS Guidance
-
Medtronic adds board members after Elliott becomes major shareholder - report
-
Medtronic (MDT) to add Directors as Elliott becomes major shareholder - WSJ
-
Medtronic poised for Q1 beat on strong product cycle, currency tailwinds
-
Raymond James on Medtronic, Inc. (MDT): 'Expecting a Strong F1Q; Consistency and Margins are Key'
-
Goldman now owns a big slug of this med-tech stock, possibly for an activist
-
Needham Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Medtronic (MDT) Declares $0.71 Quarterly Dividend; 3.1% Yield
-
Orchestra BioMed raises $111 million through equity offerings and partnerships
-
Ligand and Medtronic invest $70 million in Orchestra BioMed
-
Medtronic gets CE Mark for expanded MiniMed 780G diabetes system uses
-
Goldman Sachs Reiterates Sell Rating on Medtronic, Inc. (MDT)
-
Raymond James Reiterates Market Perform Rating on Medtronic, Inc. (MDT)
-
William Blair Out Positive on Medtronic, Inc. (MDT)
-
JPMorgan Reiterates Neutral Rating on Medtronic, Inc. (MDT)
-
BofA Securities Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
BTIG Comments on Medtronic, Inc. (MDT)
